Viatris (VTRS) said Monday that the US Food and Drug Administration has issued a warning letter and an import alert to its oral finished dose manufacturing facility in India, following an inspection earlier this year.
The import alert impacts 11 products, which will not be accepted in the US until the FDA lifts the warning letter, Viatris said.
Viatris said it has implemented a "comprehensive" remediation plan, including corrective and preventive actions, and continues to work with the FDA to address the issues raised.
The company does not anticipate these actions will affect its 2024 financial guidance and plans to update its 2025 financial guidance accordingly, Viatris said.
Viatris shares fell 0.6% in recent trading.
Price: 12.44, Change: -0.08, Percent Change: -0.62
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。